
CLAIMS


What is claimed is:

1. Use of a therapeutically effective amount of a compound having the structural formula




and/or a salt thereof, in the manufacture of a medicament for treating or reducing the symptoms of muscular dystrophy in a human patient between the age of 1 day and 18 years old, without increasing the incidence of vertebral fractures in the human patient.

2. Use of a therapeutically effective amount of a compound having the structural formula



and/or a salt thereof, in the manufacture of a medicament for treating or reducing the symptoms of muscular dystrophy in a human patient between the age of 1 day and 18 years old, without increasing the incidence of behavior adverse events in the human patient.

3. The use of claim 2, wherein the behavior adverse event is chosen from one or more of aggression, agitation, anger, emotional disorder, irritability, mood swings, sleep disorder, initial insomnia, and personality change.
4. The use of claim 3, wherein the behavior adverse event is chosen from one or more of anger, mood swings, and personality change.
5. The use of any one of claims 2–4, wherein the patient is assessed with a Pediatric Anxiety Rating Scale (PARS) III questionnaire.
6. Use of a therapeutically effective amount of a compound having the structural formula



and/or a salt thereof, in the manufacture of a medicament for treating or reducing the symptoms of muscular dystrophy in a human patient between the age of 1 day and 18 years old, without decreasing lean body composition and bone density in the human patent.

7. The use of claim 6, wherein the body composition and bone density are measured via dual-energy X-ray absorptiometry (DXA).

8. The use of any one of claims 6–7, wherein the human patient's body composition is leaner than in the human patient taking a therapeutically effective amount of prednisone or deflazacort for treating muscular dystrophy.


9. The use of any one of claims 6–8, wherein the human patient's bone density is greater than in the human patient taking a therapeutically effective amount of prednisone or deflazacort for treating muscular dystrophy.

10. The use of any one of claims 6–9, wherein total body lean mass index of the human patient showed greater positive changes in the human patient who has taken a therapeutically effective amount of prednisone for treating muscular dystrophy.

11. The use of any one of claims 6–10, wherein the rate of osteoporosis in the human patient is less than in the human patient taking a therapeutically effective amount of prednisone or deflazacort for muscular dystrophy.

12. The use of any one of claims 6–11, the difference between chronological age of the human patient and the bone age of the human patient is reduced.

13. Use of a therapeutically effective amount of a compound having the structural formula



and/or a salt thereof, in the manufacture of a medicament for treating or reducing the symptoms of muscular dystrophy in a human patient between the

age of 1 day and 18 years old, wherein the human patient demonstrates reduced positive transcriptional activity.

14. The use of any one of claims 1–13, wherein the muscular dystrophy is chosen from Duchenne muscular dystrophy and Becker muscular dystrophy.

15. The use of claim 14, wherein the muscular dystrophy is Duchenne muscular dystrophy.

16. The use of any one of claims 1–15, wherein the compound is to be administered for at least 6 months.

17. The use of claim 16, wherein the compound is to be administered for at least 12 months.

18. The use of claim 17, wherein the compound is to be administered for at least 18 months.

19. The use of claim 18, wherein the compound is to be administered for at least 24 months.

20. The use of claim 19, wherein the compound is to be administered for at least 30 months.

21. The use of any one of claims 1–20, wherein the months are consecutive.

22. The use of any one of claims 1–20, wherein the months are cumulative.

23. The use of any one of claims 1–22, wherein between about 1 mg/kg/day and about 12 mg/kg/day of the compound is to be administered.

24. The use of claim 23, wherein between about 2 mg/kg/day and about 6 mg/kg/day of the compound is to be administered.

25. The use of claim 24, wherein about 2 mg/kg/day of the compound is to be administered.

26. The use of claim 25, wherein the administration of 2 mg/kg/day of the compound has a decreased risk of weight gain for the human patient.

27. The use of claim 25, wherein about 6 mg/kg/day of the compound is to be administered.

28. The use of any one of claims 1–27, wherein the human patient is between 2 and 18 years old.

29. The use of claim 28, wherein the human patient is between 4 and 12 years old.

30. The use of claim 29, wherein the human patient is between 4 and 7 years old.

31. The use of any one of claims 1–30, wherein the human patient is male.

32. The use of any one of claims 1–31, wherein the compound is to be administered orally.

33. The use of any one of claims 1–32, wherein the compound is to be administered as a solution or suspension.

34. The use of claim 33, wherein the solution or suspension comprises about 4 wt.% of the compound.

35. The use of claim 33 or 34, wherein the solution or suspension further comprises a flavoring agent.

36. The use of any one of claims 1–35, wherein the treatment is characterized by an increased velocity for time run/walk ten meters (TTRW).

37. The use of claim 36, wherein the TTRW velocity increased by at least 0.3 meters per second.

38. The use of any one of claims 1–37, wherein the treatment is characterized by an increased velocity for time to climb four stairs (TTCLIMB).

39. The use of claim 38, wherein the TTCLIMB velocity increased by at least 0.05 stairs per second.